NCI Cancer Bulletin: A Trusted Source for Cancer Research News
NCI Cancer Bulletin: A Trusted Source for Cancer Research News
June 12, 2007 • Volume 4 / Number 19 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

Featured Article

Treatment for Advanced Liver Cancer Increases Survival

The targeted drug sorafenib (Nexavar) has improved the survival of patients with advanced liver cancer, a fatal disease that is becoming more common worldwide.

The final-stage, randomized study found that patients taking sorafenib lived nearly 3 months longer than patients taking a placebo. This was clinically significant, and the trial was stopped early because preliminary results clearly favored sorafenib. Read more  

Director's Update

ASCO 2007: Steady Progress Against Cancer

On June 1-5, Chicago played host to this year's American Society of Clinical Oncology (ASCO) meeting. This year set an attendance record with more than 30,000 participants. Throughout the meeting one sensed the excitement of steady, continued progress. There was also anticipation of even greater changes that will occur in the coming years as laboratory science is enabled by new and rapidly evolving technology. The anticipation was clearly about earlier diagnosis, new and reliable biomarkers, highly characterized tumors, and more targeted therapies.

For example, as the lead story in this issue of the NCI Cancer Bulletin discusses in greater detail, a phase III European clinical trial found that, compared with placebo, the multitargeted agent sorafenib (Nexavar) improves survival in advanced hepatocellular carcinoma (HCC). There was a small, but statistically significant, improvement, marking the first time a systemic treatment has proven effective against advanced HCC, a notoriously intractable disease that is increasing in incidence in the U.S. The result clearly sets the stage for further trials testing sorafenib in combination with other targeted agents to treat HCC. Read more  

The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI). NCI, which was established in 1937, leads the national effort to eliminate the suffering and death due to cancer. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information on cancer, call 1-800-4-CANCER or visit

NCI Cancer Bulletin staff can be reached at